Nomura Asset Management Co. Ltd. Buys 15,349 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Nomura Asset Management Co. Ltd. grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 4.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 364,587 shares of the company’s stock after acquiring an additional 15,349 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $11,379,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Allworth Financial LP grew its holdings in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after acquiring an additional 329 shares in the last quarter. Grove Bank & Trust grew its holdings in shares of Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after acquiring an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares in the last quarter. Global Retirement Partners LLC grew its holdings in shares of Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after acquiring an additional 292 shares in the last quarter. Finally, 1620 Investment Advisors Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 1,823.2% in the 4th quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock valued at $49,000 after acquiring an additional 1,495 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 10,679 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $36.00, for a total value of $384,444.00. Following the transaction, the chief accounting officer owned 20,016 shares in the company, valued at approximately $720,576. This represents a 34.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Sabag sold 144,180 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the completion of the transaction, the insider owned 80,760 shares in the company, valued at approximately $2,825,792.40. This trade represents a 64.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 491,524 shares of company stock worth $16,789,555 in the last ninety days. Insiders own 0.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TEVA. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. UBS Group lifted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. The Goldman Sachs Group lifted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Finally, Truist Financial lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Teva Pharmaceutical Industries Stock Down 4.8%

TEVA stock opened at $32.98 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The firm has a market capitalization of $37.92 billion, a PE ratio of 24.80, a PEG ratio of 3.53 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The business’s 50 day simple moving average is $32.45 and its 200 day simple moving average is $31.45.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The business had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.36 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.